Covered recipient · General Payments record
KENNETH W DAWES
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,395.83
137 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,395.83 | 137 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $625.67 | 24 |
| Novartis Pharmaceuticals Corporation | $407.68 | 33 |
| PFIZER INC. | $198.50 | 14 |
| Janssen Biotech, Inc. | $164.20 | 19 |
| Amgen Inc. | $159.51 | 11 |
| Lilly USA, LLC | $155.22 | 9 |
| Stemline Therapeutics Inc. | $112.48 | 1 |
| Janssen Research & Development, LLC | $88.84 | 1 |
| Incyte Corporation | $83.17 | 4 |
| GENZYME CORPORATION | $77.13 | 4 |
| Regeneron Healthcare Solutions, Inc. | $76.49 | 5 |
| LEO Pharma Inc. | $56.21 | 3 |
| UCB, Inc. | $52.98 | 3 |
| Acrotech Biopharma LLC | $44.58 | 1 |
| E.R. Squibb & Sons, L.L.C. | $41.90 | 2 |
| Sun Pharmaceutical Industries Inc. | $30.47 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.80 | 1 |
Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KENNETH W DAWES
NPI 1497758627 · CMS profile ID 158180
Allopathic & Osteopathic Physicians / Dermatology
INDIANAPOLIS, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KENNETH W DAWES, NPI 1497758627, CMS profile ID 158180. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). KENNETH W DAWES, NPI 1497758627, CMS profile ID 158180. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- KENNETH W DAWES, NPI 1497758627, CMS profile ID 158180, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–137 of 137 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1497758627?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
137 matching records · $2,395.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–137 of 137.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.62 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594695 | CMS |
| Lilly USA, LLC | $13.37 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918118333 | CMS |
| ABBVIE INC. | $20.38 | 03/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838643 | CMS |
| PFIZER INC. | $5.68 | 03/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949570313 | CMS |
| Amgen Inc. | $8.39 | 03/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939911961 | CMS |
| Regeneron Healthcare Solutions, Inc. | $13.08 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927144935 | CMS |
| LEO Pharma Inc. | $19.86 | 03/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936212007 | CMS |
| ABBVIE INC. | $17.75 | 03/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838641 | CMS |
| Janssen Research & Development, LLC | $88.84 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887129321 | CMS |
| ABBVIE INC. | $16.69 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838639 | CMS |
| Janssen Biotech, Inc. | $3.39 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896725 | CMS |
| Janssen Biotech, Inc. | $10.19 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896749 | CMS |
| ABBVIE INC. | $22.22 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838637 | CMS |
| Novartis Pharmaceuticals Corporation | $2.73 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594691 | CMS |
| ABBVIE INC. | $17.35 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838635 | CMS |
| Janssen Biotech, Inc. | $7.39 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896731 | CMS |
| Lilly USA, LLC | $19.42 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918158217 | CMS |
| PFIZER INC. | $6.26 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949620447 | CMS |
| Novartis Pharmaceuticals Corporation | $12.79 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594685 | CMS |
| UCB, Inc. | $14.51 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 907992639 | CMS |
| Novartis Pharmaceuticals Corporation | $119.37 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594677 | CMS |
| Regeneron Healthcare Solutions, Inc. | $13.33 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927144931 | CMS |
| PFIZER INC. | $6.08 | 02/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949189365 | CMS |
| ABBVIE INC. | $7.14 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838633 | CMS |
| Novartis Pharmaceuticals Corporation | $3.85 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594689 | CMS |
| Janssen Biotech, Inc. | $3.07 | 02/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896719 | CMS |
| Janssen Biotech, Inc. | $7.94 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896785 | CMS |
| Janssen Biotech, Inc. | $15.03 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896777 | CMS |
| ABBVIE INC. | $27.84 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838631 | CMS |
| ABBVIE INC. | $27.02 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838629 | CMS |
| Amgen Inc. | $8.26 | 01/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939911957 | CMS |
| Novartis Pharmaceuticals Corporation | $1.31 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594683 | CMS |
| Novartis Pharmaceuticals Corporation | $1.51 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594687 | CMS |
| Novartis Pharmaceuticals Corporation | $1.55 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893594681 | CMS |
| ABBVIE INC. | $18.59 | 01/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890838627 | CMS |
| Janssen Biotech, Inc. | $3.50 | 01/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896715 | CMS |
| Janssen Biotech, Inc. | $11.60 | 01/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885896773 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $83,504.70 | 17 |
| PY2025 | Principal investigator | $220,987.57 | 249 |
| PY2024 | Principal investigator | $470,955.36 | 225 |
| PY2023 | Recipient | $629.00 | 1 |
| PY2023 | Principal investigator | $411,376.39 | 220 |
| PY2022 | Principal investigator | $377,634.04 | 111 |
| PY2021 | Principal investigator | $161,324.51 | 36 |
| PY2020 | Principal investigator | $233,008.04 | 29 |
| PY2019 | Recipient | $3,500.00 | 1 |
| PY2019 | Principal investigator | $288,143.32 | 40 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
266 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $410.04 | 12/29/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431304 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $10,326.42 | 12/19/2025 | Covered Recipient Physician | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262860 |
| Principal investigator 1 | Incyte Corporation | $951.30 | 12/11/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522558 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522562 |
| Principal investigator 1 | Incyte Corporation | $220.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522569 |
| Principal investigator 1 | Incyte Corporation | $883.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522573 |
| Principal investigator 1 | Incyte Corporation | $546.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522598 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522605 |
| Principal investigator 1 | Incyte Corporation | $732.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522611 |
| Principal investigator 1 | Incyte Corporation | $132.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522617 |
| Principal investigator 1 | Incyte Corporation | $152.00 | 12/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522626 |
| Principal investigator 1 | Incyte Corporation | $7,009.30 | 12/08/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522601 |
| Principal investigator 1 | Incyte Corporation | $606.10 | 12/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522554 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521811 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521816 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522579 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522594 |
| Principal investigator 1 | Incyte Corporation | $49.77 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522614 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522630 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522633 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522641 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522645 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522649 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522653 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,008.30 | 12/01/2025 | Covered Recipient Physician | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262858 |
| Principal investigator 1 | Incyte Corporation | $4,500.00 | 11/20/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522546 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 11/20/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522550 |
| Principal investigator 1 | Incyte Corporation | $1,915.20 | 11/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522565 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 10/23/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522590 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522637 |
| Principal investigator 1 | Incyte Corporation | $2,345.00 | 10/20/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522582 |
| Principal investigator 1 | Incyte Corporation | $95.80 | 10/20/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522622 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,300.00 | 10/20/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226113726 |
| Principal investigator 1 | Incyte Corporation | $1,125.90 | 10/16/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522534 |
| Principal investigator 1 | Incyte Corporation | $951.30 | 10/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522538 |
| Principal investigator 1 | Incyte Corporation | $1,125.90 | 10/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522542 |
| Principal investigator 1 | Incyte Corporation | $2,110.50 | 10/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522586 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,302.30 | 09/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431302 |
| Principal investigator 1 | Incyte Corporation | $1,376.10 | 09/10/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522525 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 09/05/2025 | Covered Recipient Physician | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262854 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 09/05/2025 | Covered Recipient Physician | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262856 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,729.00 | 09/03/2025 | Covered Recipient Physician | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262852 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521734 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521738 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521742 |
| Principal investigator 1 | Incyte Corporation | $2.12 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521746 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521750 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521754 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521757 |
| Principal investigator 1 | Incyte Corporation | $12.72 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521766 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521771 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521775 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521782 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521786 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521790 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521799 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521803 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,792.08 | 08/22/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262850 |
| Principal investigator 1 | Incyte Corporation | $1,156.50 | 08/20/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522440 |
| Principal investigator 1 | Incyte Corporation | $1,593.00 | 08/20/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522444 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $3,637.55 | 08/20/2025 | Covered Recipient Physician | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262848 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521762 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 08/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521779 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 08/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521795 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 08/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521807 |
| Principal investigator 1 | Incyte Corporation | $1,376.10 | 08/04/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522453 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $546.72 | 07/28/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431298 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,246.20 | 07/28/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431300 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,657.20 | 07/23/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262846 |
| Principal investigator 1 | Incyte Corporation | $2,251.80 | 07/22/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240522436 |
| Principal investigator 1 | Incyte Corporation | $1,583.60 | 07/18/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522460 |
| Principal investigator 1 | Incyte Corporation | $2,345.00 | 07/18/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522464 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 07/18/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522480 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 07/18/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522484 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,085.40 | 07/18/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431296 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,985.00 | 07/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190300125 |
| Principal investigator 1 | Incyte Corporation | $1,376.10 | 07/09/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522449 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522456 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522469 |
| Principal investigator 1 | Incyte Corporation | $7.29 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522473 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522476 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522487 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522491 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522496 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522501 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522505 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522509 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522512 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522516 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522520 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 07/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522529 |
| Principal investigator 1 | Incyte Corporation | $2,345.00 | 06/25/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522369 |
| Principal investigator 1 | Incyte Corporation | $935.10 | 06/25/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522374 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 06/25/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522422 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,132.75 | 06/25/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Gro LLC | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226103889 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,302.30 | 06/18/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431294 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,287.60 | 06/11/2025 | Covered Recipient Physician | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262844 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522358 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 06/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522396 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 05/28/2025 | Covered Recipient Physician | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223262842 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,085.40 | 05/27/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431292 |
| Principal investigator 1 | Organon Llc | $2,045.10 | 05/26/2025 | Non-covered Recipient Entity RM Medical Research, Inc. | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173042008 |
| Principal investigator 1 | Eli Lilly and Company | $9,183.00 | 05/21/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187879715 |
| Principal investigator 1 | Incyte Corporation | $2,215.00 | 05/21/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522338 |
| Principal investigator 1 | Incyte Corporation | $2,215.00 | 05/21/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522345 |
| Principal investigator 1 | Incyte Corporation | $872.80 | 05/21/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522353 |
| Principal investigator 1 | Incyte Corporation | $1,376.10 | 05/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522350 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $6,939.09 | 05/07/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262840 |
| Principal investigator 1 | Incyte Corporation | $2,215.00 | 05/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522362 |
| Principal investigator 1 | Incyte Corporation | $1,094.30 | 05/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522366 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,690.00 | 04/17/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431290 |
| Principal investigator 1 | Eli Lilly and Company | $1,800.00 | 04/07/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | No dispute reported | 06/30/2026 | 1187880755 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522343 |
| Principal investigator 1 | Incyte Corporation | $28.84 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522378 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522382 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522384 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522387 |
| Principal investigator 1 | Incyte Corporation | $26.50 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522392 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522401 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522405 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522409 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522413 |
| Principal investigator 1 | Incyte Corporation | $1,169.60 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522418 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522427 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 04/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522432 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $11,192.38 | 03/26/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262838 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,085.40 | 03/24/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,342.00 | 03/19/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184174554 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,198.00 | 03/19/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184174556 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,767.70 | 03/14/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262836 |
| Principal investigator 1 | Incyte Corporation | $1,504.80 | 03/12/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521876 |
| Principal investigator 1 | Incyte Corporation | $2,336.00 | 03/05/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521873 |
| Principal investigator 1 | Incyte Corporation | $1,023.40 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521880 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522088 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522091 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522097 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522101 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522122 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522131 |
| Principal investigator 1 | Incyte Corporation | $7.29 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522135 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522139 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522143 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522145 |
| Principal investigator 1 | Incyte Corporation | $137.40 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522149 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522173 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522194 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522288 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522331 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 03/03/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522334 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,473.10 | 03/03/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431286 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,425.00 | 02/21/2025 | Non-covered Recipient Entity Dawes Fretzin Dermatology Group, Llc | A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235997756 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,290.28 | 02/21/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262834 |
| Principal investigator 1 | Incyte Corporation | $1,344.80 | 02/19/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521842 |
| Principal investigator 1 | Incyte Corporation | $1,618.00 | 02/19/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521858 |
| Principal investigator 1 | Eli Lilly and Company | $11,679.85 | 02/11/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187879791 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,860.80 | 02/07/2025 | Non-covered Recipient Entity Dawes Fretzin Clinical Research Group, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246431284 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521946 |
| Principal investigator 1 | Incyte Corporation | $3.43 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521968 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521974 |
| Principal investigator 1 | Incyte Corporation | $1.40 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521977 |
| Principal investigator 1 | Incyte Corporation | $13.60 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521981 |
| Principal investigator 1 | Incyte Corporation | $27.75 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521985 |
| Principal investigator 1 | Incyte Corporation | $190.62 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521989 |
| Principal investigator 1 | Incyte Corporation | $9.90 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521993 |
| Principal investigator 1 | Incyte Corporation | $2.94 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240521997 |
| Principal investigator 1 | Incyte Corporation | $33.96 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522000 |
| Principal investigator 1 | Incyte Corporation | $3.32 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522002 |
| Principal investigator 1 | Incyte Corporation | $0.44 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522006 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522009 |
| Principal investigator 1 | Incyte Corporation | $6.25 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522015 |
| Principal investigator 1 | Incyte Corporation | $6.88 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522020 |
| Principal investigator 1 | Incyte Corporation | $2.04 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522024 |
| Principal investigator 1 | Incyte Corporation | $29.52 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522030 |
| Principal investigator 1 | Incyte Corporation | $103.25 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522034 |
| Principal investigator 1 | Incyte Corporation | $119.08 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522039 |
| Principal investigator 1 | Incyte Corporation | $9.45 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522043 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522046 |
| Principal investigator 1 | Incyte Corporation | $120.06 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522050 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522054 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522058 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522062 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522066 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522069 |
| Principal investigator 1 | Incyte Corporation | $1.47 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522074 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522078 |
| Principal investigator 1 | Incyte Corporation | $6.52 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522081 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522085 |
| Principal investigator 1 | Incyte Corporation | $76.92 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522106 |
| Principal investigator 1 | Incyte Corporation | $54.62 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522110 |
| Principal investigator 1 | Incyte Corporation | $22.29 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522114 |
| Principal investigator 1 | Incyte Corporation | $22.29 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522118 |
| Principal investigator 1 | Incyte Corporation | $24.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522127 |
| Principal investigator 1 | Incyte Corporation | $12.20 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522154 |
| Principal investigator 1 | Incyte Corporation | $3.43 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522163 |
| Principal investigator 1 | Incyte Corporation | $6.76 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522169 |
| Principal investigator 1 | Incyte Corporation | $43.32 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522190 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522204 |
| Principal investigator 1 | Incyte Corporation | $104.56 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522211 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522222 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522226 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522229 |
| Principal investigator 1 | Incyte Corporation | $58.78 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522233 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522237 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522241 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522244 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522249 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522253 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522257 |
| Principal investigator 1 | Incyte Corporation | $9.90 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522322 |
| Principal investigator 1 | Incyte Corporation | $9.90 | 02/06/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream | No dispute reported | 06/30/2026 | 1240522326 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $9,769.51 | 02/05/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262832 |
| Principal investigator 1 | Organon Llc | $2,623.20 | 02/03/2025 | Non-covered Recipient Entity RM Medical Research, Inc. | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173041982 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,772.07 | 02/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190308122 |
| Principal investigator 1 | Incyte Corporation | $1,572.00 | 01/27/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521846 |
| Principal investigator 1 | Incyte Corporation | $1,572.00 | 01/27/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521850 |
| Principal investigator 1 | Incyte Corporation | $1,679.10 | 01/27/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521861 |
| Principal investigator 1 | Incyte Corporation | $2,111.40 | 01/17/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521828 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 01/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521819 |
| Principal investigator 1 | Incyte Corporation | $1,572.00 | 01/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521823 |
| Principal investigator 1 | Incyte Corporation | $487.50 | 01/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521832 |
| Principal investigator 1 | Incyte Corporation | $1,572.00 | 01/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521838 |
| Principal investigator 1 | Incyte Corporation | $2,215.00 | 01/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521854 |
| Principal investigator 1 | Incyte Corporation | $1,462.00 | 01/15/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522186 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $4,747.93 | 01/08/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262830 |
| Principal investigator 1 | Organon Llc | $3,300.00 | 01/07/2025 | Non-covered Recipient Entity RM Medical Research, Inc. | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | No dispute reported | 06/30/2026 | 1173041974 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $7,559.66 | 01/03/2025 | Covered Recipient Physician | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223262828 |
| Principal investigator 1 | Incyte Corporation | $164.30 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521865 |
| Principal investigator 1 | Incyte Corporation | $185.50 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521868 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521884 |
| Principal investigator 1 | Incyte Corporation | $79.50 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521888 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521893 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521897 |
| Principal investigator 1 | Incyte Corporation | $47.70 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521903 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521907 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521911 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521915 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521919 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521925 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521930 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521934 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521938 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521942 |
| Principal investigator 1 | Incyte Corporation | $6.18 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521950 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521956 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521960 |
| Principal investigator 1 | Incyte Corporation | $7.29 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240521964 |
| Principal investigator 1 | Incyte Corporation | $15.90 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522158 |
| Principal investigator 1 | Incyte Corporation | $127.20 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522177 |
| Principal investigator 1 | Incyte Corporation | $127.20 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522183 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522199 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522207 |
| Principal investigator 1 | Incyte Corporation | $74.20 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522218 |
| Principal investigator 1 | Incyte Corporation | $79.50 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522261 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522265 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522270 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522277 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522281 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522285 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522293 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522297 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522301 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522304 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522308 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522312 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH GROUP LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240522318 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,249.36 | 01/01/2025 | Non-covered Recipient Entity DAWES FRETZIN CLINICAL RESEARCH | A randomized subject and investigator blinded placebo controlled and multi center platform study to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1190308120 |